Tarsus execs discuss origins, treating Demodex blepharitis

February 4, 2021
OT Staff Reports

Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.

See more AAO coverage